Latigo Biotherapeutics, Inc. - 8-K Filing
Latigo Biotherapeutics appoints Todd Smith as CEO, replaces Nima Farzan, and reports Q3 2026 cash position of $401.2 million (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $LTGO